A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
Clinical trial NCT02713867 · COMPLETED
Trial details
- NCT number
- NCT02713867
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-24
- Primary completion
- 2019-07-15
- Enrollment
- 363
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.